Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05634707 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
A Early Phase 1 study of Primary Brain Tumor and Brain Tumor, Recurrent, sponsored by Duke University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT05634707 is a Early Phase 1 study of Primary Brain Tumor and Brain Tumor, Recurrent that is active but no longer recruiting, run by Duke University. The registered enrollment target is 10 participants, below the 84-participant average among 7 other Primary Brain Tumor trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05634707, a Early Phase 1 study of Primary Brain Tumor and Brain Tumor, Recurrent, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery. Lysosomes are organelles (structures in cells) that contain digestive enzymes (substances that break down chemicals) that help keep the cells free of extra or worn out cell parts. Fluoxetine, a drug approved by the FDA to treat problems like depression and anxiety, can cause changes to structures in cells called lysosomes that then improve how well the chemotherapy drug temozolomide (TMZ) kills cancer cells in the brain.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Fluoxetine
Study Locations (4)
California
- UC San Diego Moores Cancer Center - San Diego
- Stanford Cancer Institute - Stanford
New York
- NYU Langone Health - New York
North Carolina
- The Preston Robert Tisch Brain Tumor Center at Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-08-05 |
| Est. Completion | 2027-06-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05634707
The ClinicalTrials.gov registry entry for NCT05634707 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 7 other Primary Brain Tumor trials with a reported enrollment target (88% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Brain Tumor appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT05634707 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05634707 about?
NCT05634707 is a clinical study titled "Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)". The purpose of this research study is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery. Lysosomes are organelles (structures in cells) that contain digest...
What is the current status of trial NCT05634707?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2023-08-05. Estimated completion is 2027-06-05.
What conditions does trial NCT05634707 study?
This clinical trial studies the following conditions: Primary Brain Tumor, Brain Tumor, Recurrent.
What interventions are being tested in trial NCT05634707?
The interventions under investigation include: Temozolomide (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT05634707?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05634707 being conducted?
This trial has 4 study locations across California, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RECRUITING
-
Assessment of Eloquent Function in Brain Tumor Patients
RECRUITING
-
Non-invasive Glioma Characterization Through Molecular Imaging
RECRUITING · NA
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
RECRUITING · Phase 1
-
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.